Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
The Methodist Hospital System Bayer |
---|---|
Information provided by: | The Methodist Hospital System |
ClinicalTrials.gov Identifier: | NCT00450008 |
The purpose of this study is to assess the relative efficacy and toxicity of combination therapy of GM-CSF, Thalidomide plus Docetaxel in patients with prostate cancer with a rising PSA.
Condition | Intervention | Phase |
---|---|---|
Prostatic Neoplasms |
Drug: GM-CSF Drug: thalidomide Drug: docetaxel |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Phase II Study of Patients With Hormone-Naïve Prostate Cancer With a Rising Prostate Specific Antigen: Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), Thalidomide Plus Docetaxel |
Enrollment: | 9 |
Study Start Date: | December 2006 |
Estimated Study Completion Date: | September 2008 |
Primary Completion Date: | August 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
A
Combination therapy of GM-CSF, Thalidomide plus Docetaxel in patients with prostate cancer with a rising PSA
|
Drug: GM-CSF
fixed dose of 250 mcg/m2, 3 days per week by subcutaneous injection
Drug: thalidomide
Thalidomide by oral administration at a fixed dose of 200 mg. Prophylactic Coumadin® by oral administration at a fixed dose of 2.5 mg to prevent thromboembolic events (DVT and TIA/stroke) during Thalidomide administration. Thalidomide and Coumadin will be given daily at bedtime without interruption.
Drug: docetaxel
Docetaxel will be administered by intravenous piggyback over 1 hour at 75mg/m² every 3 weeks. Pre-medication for the docetaxel infusion will consist of dexamethasone 8 mg administered orally 12 hours, 3 hours and 1 hour before docetaxel.
|
As more men are being diagnosed and treated for prostate cancer at an early age, the number who experiences a rising level of prostate-specific antigen (PSA) after initial treatment is increasing, affecting approximately 50,000 patients each year.
These three drugs are commercially available. Thalidomide is an angiogenesis inhibitor which blocks the development of new blood vessels. GM-CSF stimulates the body's immune response to fight cancer. Docetaxel is the most active chemotherapeutic agent in the treatment of prostate cancer. GM-CSF and thalidomide have proven activity in suppressing PSA values.
This study design offers an opportunity to add cytotoxic therapy (docetaxel) in combination with an active pathobiologic regimen (GM-CSF plus thalidomide) to eradicate micrometastatic disease, thus potentially offering a significant delay to clinical failure as measured by a rise in PSA or radiographic involvement. Additionally, delays in the use of hormone therapy has the potential to be of significant benefit.
GM-CSF will be administered at a fixed dose 3 days per week by subcutaneous injection for 12 months. Participants will receive a fixed dose of thalidomide orally at bedtime daily without interruption for 12 months. Docetaxel will be administered intravenously over 1 hour on week 1 of every cycle (every 3 weeks) for 18 weeks.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Texas | |
The Methodist Hospital Research Institute | |
Houston, Texas, United States, 77030 |
Principal Investigator: | Robert J Amato, DO | The Methodist Hospital Research Institute |
Responsible Party: | The Methodist Hospital Research Institute ( Robert J. Amato, DO ) |
Study ID Numbers: | PCa-06-102, 1006-0153 |
Study First Received: | March 19, 2007 |
Last Updated: | August 21, 2008 |
ClinicalTrials.gov Identifier: | NCT00450008 |
Health Authority: | United States: Institutional Review Board |
Prostate Cancer Hormone-Naïve Prostate Cancer adenocarcinoma of the prostate |
Docetaxel Dexamethasone Thalidomide Prostatic Diseases Genital Neoplasms, Male Urogenital Neoplasms |
Warfarin Genital Diseases, Male Adenocarcinoma Prostatic Neoplasms Dexamethasone acetate |
Anti-Infective Agents Immunologic Factors Antineoplastic Agents Growth Substances Physiological Effects of Drugs Immunosuppressive Agents Angiogenesis Inhibitors Pharmacologic Actions |
Anti-Bacterial Agents Neoplasms Neoplasms by Site Therapeutic Uses Growth Inhibitors Angiogenesis Modulating Agents Leprostatic Agents |